肺腺癌论文晚期肺腺癌患者一线化疗后吉非替尼维持治疗临床观察.doc

肺腺癌论文晚期肺腺癌患者一线化疗后吉非替尼维持治疗临床观察 [摘要] 目的 评价晚期肺腺癌患者一线予含铂两药联合化疗后予吉非替尼维持治疗的有效性及安全性。方法 收集我院2007年8月-2009年2月23例经病理组织学和（或）细胞学检查确诊的晚期肺腺癌患者，男7例，女16例，中位年龄63岁（39岁-73岁），均行含铂的三代药物（如紫杉醇，多西紫杉醇，培美曲赛，长春瑞滨）两药联合方案化疗2~4周期，疗效评价为部分缓解(pr）及稳定（sd）后,予吉非替尼维持治疗，吉非替尼250mg每日一次，持续服药至疾病进展或出现不可耐受得毒副反应。结果 除1例患者服药1个月后因经济原22例患者均可评价疗效，其中完全缓解（cr）1例，部分缓解（pr）7例，稳定（sd）10例，进展（pd）4例，有效率36.4%，临床获益率81.8%，中位中位无疾病进展生存期约为9个月，1年生存率72.7%，不良反应主要为皮疹及腹泻，对症治疗后均可耐受。结论 予晚期肺腺癌患者一线予含铂两药联合化疗后予吉非替尼维持治疗获得了较好疗效，且不良反应轻，耐受性好。 [关键词] 吉非替尼; 肺腺癌; 维持治疗 clinical observation of continuous maintenance therapy (cmt) with gefitinib after first-line chemotherapy of lung adenocarcinoma lijundong xu shuliren xiaoan (the no.5 peoples hospital,dalain 116021,p.r china) [abstract] objective to evaluate the effects and security of continuous maintenance therapy (cmt) with gefitinib after first-line chemotherapy of lung adenocarcinoma.methodstotally 23 patients were enrolled with adenocarcinoma of lung diagnosed by patholo clinical observation of continuous maintenance therapy (cmt) with gefitinib after gy or cytology. 7 of patients were men, 16 were women, the median age was 63years (from 39 to 73 years). the patients received combined region with third-generation platinum at least 2 cycles, after the evaluation of pr or sd, received cmt with gefitinib at the dose of 250mg/m2/day till pd or couldnt tolerant in the side reaction.resultsamong 23 patients, 22 were curative, 1 got cr, 7 were pr, 10 were sd and 4 got pd, the overall response rate (cr+pr) was 36.4%, the clinical benefit rate (cr+pr+sd) was 81.8%, the median ttp was 9 months, 1 year survival rate was 72.7%. the main side effects were gastrointestinal reaction and diarrhea, but were tolerable.conclusionthe regimen of cmt with gefitinib after first-line chemotherapy of lung adenocarcinoma has well clinical benefit rate, slight adverse reaction. [keywords] gefitinib; lung adenocarcinoma; continuous maintenance therapy (cmt) 肺癌是一种常见的恶性肿瘤，具有高发病率及高死亡率，因此肺癌治疗越来越受到肿瘤界关注。约70%-80%肺癌患者就诊时已为晚期，失去手术时机，